Select Language
CTLA-4 / CD28 Signaling Pathway: Empowering Next-Generation Immunotherapy
As a member of the immunoglobulin superfamily, CTLA-4 (Cytotoxic T-Lymphocyte Associated Protein 4) serves as a critical "molecular brake" in immune regulation. It is mainly expressed on the surface of activated T cells (CD4+ and CD8+) and is constitutively highly expressed on regulatory T cells (Treg), acting as a pivotal checkpoint for regulating immunosuppressive functions and maintaining immune homeostasis.
The T cell activation "switch" is coordinately regulated by the interplay of CD28 (costimulatory) and CTLA-4 (coinhibitory) receptors with their shared ligands, B7-1 (CD80) and B7-2 (CD86), on Antigen-Presenting Cells (APCs):
1. The Activation Signaling: Upon TCR-mediated recognition of the MHC-peptide complex (Signal 1), CD28 binds to APC-expressed B7 molecules (B7-1 or B7-2) to deliver a vital costimulatory signal (Signal 2). This initiates T cell immune responses, promotes T cell proliferation, upregulates cytokine secretion (e.g., IL-2), and enhances T cell effector functions (e.g., CD8+ T cell cytotoxicity).
2. The Inhibitory Signaling: CTLA-4 exhibits a significantly higher affinity for B7 molecules than CD28, and thus preferentially binds to B7 molecules to competitively abrogate CD28-B7-mediated costimulatory signals. This eliminates the critical costimulatory boost for T cell activation and thereby prevents tissue damage induced by excessive immune activation.
Therapeutic Strategies and Clinical Landscape
The CTLA-4/CD28 pathway has become a cornerstone in oncology and autoimmune disease research. Current therapeutic strategies focus on:
>>> Scroll to view
To meet the rigorous demands of drug development targetingCTLA-4/CD28/B7-1/B7-2, we have developed a specialized product matrix covering the entire R&D lifecycle.
• Recombinant Proteins: Multiple species (Human, Mouse, NHP) & tags (His, Fc, Avi).
• Inhibitor Screening Kits: Rapid, ready-to-use kits for B7-1/B7-2: CTLA-4 interaction.
• Anti-CD28 Antibodies: Fluorescently labeled, Premium Grade (PG), and GMP-grade for cell activation & sorting.
• Customization Services: Customized products and technical support on demand.
Key Advantages of Target Proteins
High purity and native structure verified by MALS/HPLC
High bioactivity verified by ELISA/SPR/FACS, etc.
Strict QC inspection ensures high batch-to-batch consistency
Product List
CTLA4
B7-1(CD80)
B7-2(CD86)
CD28
| Cat. No. | Molecule | Nature | Product Description | Order Now |
|---|---|---|---|---|
Protein |  Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Protein | Order | |||
Kits | Order | |||
Kits | Order | |||
Antibody | Order |
Verification Data
MALS-Verified CTLA-4 Dimer Structure
Human CTLA-4, Fc Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 98%. The purity of Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) is more than 90% and the molecular weight of this protein is around 82-100 kDa verified by SEC-MALS.
Request Report
High Binding Activity of B7-2 and CTLA-4 Verified by ELISA
Immobilized Human B7-2, His Tag (Cat. No. CD6-H5223) at 10 μg/mL (100 μL/well) can bind Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) with a linear range of 2-78 ng/mL (QC tested).
Request Protocol
High Binding Activity of CD28 and B7-1 Verified by ELISA
Immobilized Biotinylated Mouse CD28, His,Avitag (Cat. No. CD8-M82E3) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Human B7-1, Mouse IgG2a Fc Tag (Cat. No. B71-H52A4) with a linear range of 0.2-5 ng/mL (Routinely tested).
Request Protocol
Binding Activity of CTLA-4 and Cadonilimab (PD-1 x CTLA-4 BsAb) Verified by ELISA
Immobilized Human CTLA-4, His Tag (Cat. No. CT4-H5229) at 5 μg/mL, add increasing concentrations of Cadonilimab (PD-1 x CTLA-4 bispecific antibody) and then add Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) at 0.2 μg/mL. (Routinely tested).
Request Protocol
Binding Activity of CTLA-4 and Ipilimumab Verified by SPR
Biotinylated Human CTLA-4, His,Avitag (Cat. No. CT4-H82E3) captured on Biotin CAP - Series S sensor Chip can bind Yervoy (Ipilimumab) with an affinity constant of 0.635 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Request Protocol
Anti-CTLA-4 Neutralizing Antibody Screening via B7-1 [Biotinylated]: CTLA-4 Inhibitor Screening Kit
![Anti-CTLA-4 Neutralizing Antibody Screening via B7-1 [Biotinylated]: CTLA-4 Inhibitor Screening Kit](https://console.acrobiosystems.com/public/images/CKP_CTLA4/CTLA4DataA8.jpg)
Serial dilutions of Anti-CTLA-4 Neutralizing antibody (Catalog # EP116-C04) (1:1 serial dilution, from 10 μg/mL to 0.078μg/mL) was added into CTLA-4: Biotinlated B7-1 binding reactions. The assay was performed according to the protocol described below. (QC tested).
Quantitative Detection of CTLA-4×OX40 BsAb in Human Serum by ELISA
Quantitative Analysis of CTLA-4 x OX40 Bispecific Antibody in Human Serum by Intact Assay.
Immobilized Human OX40 Protein, His Tag (MALS verified) (Cat. No. OX0-H5224) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 bispecific antibody in 50% Human serum and then add Biotinylated Human CTLA-4, His, Avitag (Cat. No. CT4-H82E3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 4 ng/mL (Intact assay, Routinely tested).
Request Protocol
CTLA-4 Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| B7-2/GM-CSF cancer gene therapy | CIT | Phase 1 Clinical | Radient | Neoplasms | Details |
| BAT-4706 | BAT-4706 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Melanoma; Solid tumours | Details |
| SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| TWP-102 | TWP-102 | Phase 1 Clinical | Therawisdom Biopharma Co Ltd | Neoplasms | Details |
| Imiquimod/Zalifrelimab | UGN-302; UGN-201+UGN-301 | Phase 1 Clinical | Urogen Pharma | Urinary Bladder Neoplasms | Details |
| IMD-303 | IMD-303; IMD303 | Phase 1 Clinical | Shanghai Affinity Biopharmaceutical Co Ltd | Solid tumours | Details |
| KM602 | KM602; KM-602; XZP-KM602 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours | Details |
| STW204/Gotistobart | AI-061 | Phase 1 Clinical | Oncoc4 Inc | Anus Neoplasms; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| GK-201 | GK201; GK-201 | Phase 1 Clinical | Suzhou Guokuang Pharmaceutical Tech Co Ltd | Solid tumours | Details |
| BZE-2209 | BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T Cells | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Solid tumours | Details |
| A-337 (Klus Pharma) | A337 (Klus Pharma); A-337 (Klus Pharma) | Phase 1 Clinical | Klus Pharma Inc | Neoplasms | Details |
| GB-268 | GB268 | Phase 1 Clinical | Genor Biopharma Co Ltd | Neoplasms; Solid tumours | Details |
| CTLA-4 Mab (Beijng Immunoah Pharma Tech) | 5E3 (Beijng Immunoah Pharma Tech); CTLA-4 Mab (Beijng Immunoah Pharma Tech) | Phase 1 Clinical | Beijng Immunoah Pharma Tech Co Ltd | Solid tumours | Details |
| GIGA-564 | GIGA-564 | Phase 1 Clinical | GigaGen Inc | Solid tumours | Details |
| SAL-008 | SAL-008 | Phase 1 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Neoplasms | Details |
| Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical) | MV-049 | Phase 1 Clinical | Beijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd | Solid tumours | Details |
| BMS-986218 (Bristol-Myers Squibb) | BMS-986218 | Phase 1 Clinical | Bristol-Myers Squibb Company | Adrenal Gland Neoplasms; Liver Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| Anti-CTLA-4 monoclonal antibody (Regeneron) | REGN-4659 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
| Bavunalimab | XmAb-22841; XmAb-841 | Phase 1 Clinical | Xencor Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Penile Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| KN-044 | KN-044 | Phase 1 Clinical | Suzhou Alphamab Co Ltd | Small Cell Lung Carcinoma; Solid tumours | Details |
| JS-007 | JS007; JS-007 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Carcinoma, Hepatocellular; Lung Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) | Phase 2 Clinical | Shanghai Zhongshan Hospital | Cholangiocarcinoma | Details | |
| Muzastotug | ADG-126 | Phase 2 Clinical | Adagene Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Neoplasms; Solid tumours | Details |
| RP-3 | RP-3 | Phase 2 Clinical | Replimune Inc | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Vilastobart | XTX-101; XTX101 | Phase 2 Clinical | Xilio Development Inc | Colorectal Neoplasms | Details |
| IMM-27M | IMM-27M; IMM27M; SYN27M; SYN-27M | Phase 2 Clinical | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasms; Pathologic Processes; Solid tumours | Details | |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| SV-102 | SV-102; SV102; SYNC-T SV-102 | Phase 2 Clinical | Syncromune Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| Efzilonkofusp alfa | GI-102 | Phase 2 Clinical | GI Innovation Inc | Astrocytoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Gliosarcoma; Liver Neoplasms; Melanoma; Ovarian Neoplasms; Skin Melanoma; Soft Tissue Neoplasms; Solid tumours | Details |
| HC-010(Shanghai Hongcheng) | HC-010; HC010 | Phase 2 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| COYA-302 | COYA 302; COYA-302; COYA302 | Phase 2 Clinical | Coya Therapeutics Inc | Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Parkinson Disease | Details |
| CS-2009 | CS-2009 | Phase 2 Clinical | Cstone Pharmaceuticals | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms | Details |
| EGL-001 | EGL-001 | Phase 2 Clinical | Egle Therapeutics | Neoplasms; Solid tumours | Details |
| HX-044 | HX044; HX-044 | Phase 2 Clinical | Hanx Biopharmaceuticals Pty Ltd | Lymphoma; Solid tumours | Details |
| LM-168 | LM-168 | Phase 2 Clinical | LaNova Medicines Ltd | Solid tumours | Details |
| Firastotug | ADG-116 | Phase 2 Clinical | Adagene (Suzhou) Ltd | Solid tumours | Details |
| Apalulizumab | Phase 2 Clinical | Shanghai Rui Jin Hospital | Pancreatic Neoplasms | Details | |
| GI-101 | SIM-323; SIM323; SIM0323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| Sovipostobart | BMS-986249 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
| JK-08 | JK-08 | Phase 2 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Triple Negative Breast Neoplasms | Details |
| Porustobart | HBM-4003; HCAb 4003-2 | Phase 2 Clinical | Harbour Biomed | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Neoplasms; Neuroendocrine Tumors; Solid tumours | Details |
| KD-6001 | KD-6001 | Phase 2 Clinical | Shanghai Celgen Bio-Pharmaceutical Co Ltd, Shanghai Kanda Bio-Technology Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms; Melanoma; Neoplasms; Solid tumours | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| Zalifrelimab | AGEN-1884; RebmAb-600; UGN-301 | Phase 2 Clinical | 4-Antibody AG, Ludwig Institute For Cancer Research | Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Hemangiosarcoma; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Quavonlimab | AK-107; MK-1308 | Phase 2 Clinical | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details | |
| Abatacept (Orban Biotech) | Phase 2 Clinical | Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases | Diabetes Mellitus, Type 1 | Details | |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital of Navy Medical University | Pancreatic Neoplasms | Details | |
| Belatacept biosimilar (Alphamab) | KN-019 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Arthritis, Rheumatoid; Rejection of renal transplantation | Details |
| Lorigerlimab | MGD-019; AEX1344 | Phase 2 Clinical | Macrogenics Inc | Adenocarcinoma, Clear Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Hormone-Resistant Prostate Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Clear Cell Carcinoma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Skin Melanoma; Solid tumours; Uterine Cervical Neoplasms | Details |
| Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) | Phase 2 Clinical | Hualan Ankang Biotechnology Co Ltd | Melanoma | Details | |
| Vudalimab | XmAb-717; XmAb-20717; XmAb 717 | Phase 2 Clinical | Xencor Inc | Adenocarcinoma, Clear Cell; Adenoma, Acidophil; Adnexal Diseases; Astrocytoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Castration-Sensitive Prostate Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Melanoma; Mesothelioma; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms | Details |
| Evalstotug | CAB-CTLA-4; BA-3071 | Phase 2 Clinical | BeOne Medicines Ltd, Bioatla | Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| BMS-986288 | BMS-986288 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
| Danvilostomig | SI-B003 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Metastatic breast cancer; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| Futermestotug | YH-001 | Phase 2 Clinical | Alopecia Areata; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Sarcoma; Solid tumours | Details | |
| Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D（China）Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Small Cell Lung Carcinoma; Solid tumours | Details |
| Nurulimab/Prolgolimab | BCD-217; BCD-145/BCD-100 | Phase 3 Clinical | BIOCAD JSC | Melanoma; Skin Melanoma | Details |
| Ipilimumab biosimilar (Henlius) | HLX13 | Phase 3 Clinical | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Melanoma; Mesothelioma; Solid tumours | Details | |
| Volrustomig | MEDI5752; MEDI-5752 | Phase 3 Clinical | Medimmune Llc | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Mesothelioma; Papillomavirus Infections; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Erfonrilimab | KN-046 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Lymphoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Triple Negative Breast Neoplasms | Details |
| Gotistobart | ONC-392; BNT316; BNT-316 | Phase 3 Clinical | Oncoimmune Inc | Anorectal disorders; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Melanoma; Metastatic breast cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Salivary Gland Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Sturlimogene Erparepvec | RP-2 | Phase 3 Clinical | Replimune Group Inc | Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Neoplasms; Precancerous Conditions; Stomach Neoplasms; Uveal melanoma | Details |
| Botensilimab | AGEN-1181 | Phase 3 Clinical | Agenus Inc | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fibrolamellar hepatocellular carcinoma; Glioblastoma; Gliosarcoma; Hemangiosarcoma; Liver Neoplasms; Melanoma; Microsatellite Instability; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| CS-1002 | CS-1002; SHR-8068 | Phase 3 Clinical | Cstone Pharmaceuticals | Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
Recommended Related Products
Resources
Resource download
- Background
- Therapeutic Strategies and Clinical Landscape
- Key Advantages of Target Proteins
- Product List
- Verification Data
- CTLA-4 Clinical Drug Information
- Recommended Related Products
- Resources
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호